Provided by Tiger Fintech (Singapore) Pte. Ltd.

ALX Oncology Holdings

0.4526
-0.0051-1.11%
Post-market: 0.46990.0173+3.82%19:19 EDT
Volume:220.72K
Turnover:99.89K
Market Cap:24.19M
PE:-0.18
High:0.4620
Open:0.4620
Low:0.4433
Close:0.4577
Loading ...

ALX Oncology Q4 Basic EPS USD -0.55

THOMSON REUTERS
·
07 Mar

ALX Oncology Q4 Income From Operations USD -30.613 Million

THOMSON REUTERS
·
07 Mar

Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)

TIPRANKS
·
07 Mar

ALX Oncology Holdings Inc : Jefferies Raises to Buy From Hold; Raises Target Price to $3 From $2

THOMSON REUTERS
·
06 Mar

Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $3 From $2

MT Newswires Live
·
06 Mar

ALX Oncology Raised to Buy From Hold by Jefferies

Dow Jones
·
06 Mar

ALX Oncology Holdings: Undervalued with Promising Catalysts and Growth Opportunities

TIPRANKS
·
06 Mar

BRIEF-Alx Oncology Holdings Inc To Reduce Workforce By 30%

Reuters
·
06 Mar

ALX Oncology Holdings Inc - Expects $2.2 Million in Severance Expenses

THOMSON REUTERS
·
06 Mar

ALX Oncology Holdings Inc - Workforce Reduction Expected to Complete by End of May 2025

THOMSON REUTERS
·
06 Mar

ALX Oncology to Cut Workforce by 30% to Support New Clinical Initiatives

MT Newswires Live
·
05 Mar

ALX Oncology will highlight progress across its clinical pipeline

TIPRANKS
·
05 Mar

ALX Oncology Holdings Inc expected to post a loss of 67 cents a share - Earnings Preview

Reuters
·
04 Mar

February 2025 US Penny Stocks With Promising Prospects

Simply Wall St.
·
19 Feb

UBS Cuts Price Target on ALX Oncology Holdings to $2.20 From $4, Keeps Buy Rating

MT Newswires Live
·
27 Jan

ALX Oncology Holdings Inc : UBS Cuts Target Price to $2.2 From $4

THOMSON REUTERS
·
27 Jan

ALX Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
24 Jan

ALX Oncology Shares Drop 15% Following Positive Phase 2

GuruFocus.com
·
24 Jan

BRIEF-Alx Oncology Presents Positive Updated Data From Aspen-06 Phase 2 Trial

Reuters
·
23 Jan

ALX Oncology Presents Positive Updated Data From Aspen-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients With Her2-Positive Gastric Cancer

THOMSON REUTERS
·
23 Jan